Merck (MRK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended December 2024, Merck (MRK) reported revenue of $15.62 billion, up 6.8% over the same period last year. EPS came in at $1.72, compared to $0.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.55 billion, representing a surprise of +0.45%. The company delivered an EPS surprise of +1.78%, with the consensus EPS estimate being $1.69.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Merck performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Sales- Oncology- Keytruda - U.S. $4.84 billion versus the four-analyst average estimate of $4.65 billion. The reported number represents a year-over-year change of +21.9%. Sales- Oncology- Keytruda - International: $3 billion versus $3.09 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.7% change. Sales- Virology- Isentress - U.S. $38 million versus $26.83 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -24% change. Sales- Animal health - U.S. $444 million versus $415.96 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.7% change. Sales- Animal health: $1.40 billion compared to the $1.34 billion average estimate based on four analysts. The reported number represents a change of +9.3% year over year. Sales- Oncology- Keytruda: $7.84 billion versus the four-analyst average estimate of $7.73 billion. The reported number represents a year-over-year change of +18.6%. Sales- Hospital Acute Care- Prevymis: $215 million versus $206.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22.9% change. Sales- Oncology- Alliance revenue- Reblozyl: $110 million versus the three-analyst average estimate of $100.97 million. The reported number represents a year-over-year change of +57.1%. Sales- Virology- Lagevrio: $121 million compared to the $125.72 million average estimate based on three analysts. The reported number represents a change of -37.3% year over year. Sales- Vaccines- Vaxneuvance: $161 million versus the three-analyst average estimate of $220.27 million. The reported number represents a year-over-year change of -8.5%. Sales- Hospital Acute Care- Zerbaxa: $70 million compared to the $65.05 million average estimate based on three analysts. The reported number represents a change of +14.8% year over year. Sales- Oncology- Alliance Revenue- Lynparza: $365 million versus the three-analyst average estimate of $357.57 million. The reported number represents a year-over-year change of +15.9%. View all Key Company Metrics for Merck here>>>Shares of Merck have returned +0.1% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks